Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00768989 · ClinicalTrials.gov registry record · Phase 2

Phase IIB Pilot of Atazanavir + Raltegravir

A Phase 2 study, sponsored by Bristol-Myers Squibb.

Terminated
Registry status
Phase 2
Development phase
167
Enrollment target

NCT00768989: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.

NCT00768989 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 167 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00768989, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.

TERMINATED
Registry status
Phase 2
Development phase
167 participants
Enrollment target

Study Summary

The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).

Primary Outcome

The number of HIV 1-infected treatment-naive participants with an HIV RNA level \<50 copies/mL after 24 weeks of treatment. Confirmed virologic response noncompleter=failure (NC=F); noncompleter=missing (NC=M); virologic response-observed cases (VR-OC).

Interventions

  • DRUG Ritonavir
  • DRUG Atazanavir
  • DRUG Raltegravir
  • DRUG Tenofovir/Emtricitabine

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2008-11
Est. Completion 2010-05
Phase Phase 2
Bristol-Myers Squibb

1,025 total trials

Why NCT00768989 stopped before completion

NCT00768989 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).

The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.

NCT00768989 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00768989 about?

NCT00768989 is a clinical study titled "Phase IIB Pilot of Atazanavir + Raltegravir". The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).

What is the current status of trial NCT00768989?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2008-11. Estimated completion is 2010-05.

What interventions are being tested in trial NCT00768989?

The interventions under investigation include: Ritonavir (DRUG), Atazanavir (DRUG), Raltegravir (DRUG), Tenofovir/Emtricitabine (DRUG).

Who is sponsoring clinical trial NCT00768989?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00768989's enrollment target sits among peer trials

167 406th of 2000 higher than 1,595 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04248283 · 167 participants · NA

    Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

  • NCT04552509 · 167 participants · NA

    TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

  • NCT05516277 · 167 participants · NA

    Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder

  • NCT02118922 · 168 participants

    A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00768989, the US trial registry maintained by the National Library of Medicine. NCT00768989 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.